Chronic hepatitis C - What do the new drugs offer and who should get them first?

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 15, Issue 2, 2015, Pages 197-200

  Ryder, Stephen D ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DACLATASVIR; DIRECT ANTIVIRAL AGENT; LEDIPASVIR; OMBITASVIR; PARITAPREVIR; RIBAVIRIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; UNCLASSIFIED DRUG;

HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 6; HIGH RISK POPULATION; HUMAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MIXED INFECTION; RISK FACTOR; SHORT SURVEY; THERAPY DELAY; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; VIROLOGY;

ANTIVIRAL AGENTS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS;

EID: 84927942603     PISSN: 14702118     EISSN: 14734893     Source Type: Journal    
DOI: 10.7861/clinmedicine.15-2-197     Document Type: Short Survey

References (9)

1. Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM. Structural biology of hepatitis C virus. Hepatology 2004;39:5-19.
2. Woerz I, Lohmann V, Bartenschlager R. Hepatitis C virus replicons: dinosaurs still in business? J Viral Hepat 2009;16:1-9.
3. Liang TJ, Ghany MG. Therapy of hepatitis C-back to the future. N Engl J Med 2014;370:2043-7.
4. Sulkowski MS, Gardiner DF, Rodriguez-Torres M et al. Daclatasvir plus sofosbuvir for previously treated or untreated hepatitis C infection. N Engl J Med 2014;370:211-21.
5. Harris H. Hepatitis C in the UK: 2014 report. London: Public Health England, 2014. Available online at www.gov.uk/government/uploads/system/uploads/attachment-data/file/337115/HCV-in-the-UK-2014-24-July.pdf [Accessed 26 January 2015].
6. Harris RJ, Hope VD, Morongiu A, Hickman M, Ncube F, DE Angelis D. Spatial mapping of hepatitis C prevalence in recent injecting drug users in contact with services. Epidemiol Infect 2012;140:1054-63.
7. Martin NK, Foster GR, Vilar J et al. HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact. J Viral Hepat 2014 Oct 7, epub ahead of print.
8. Harris RJ, Thomas B, Griffiths J et al. Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: modelling the predicted impact of treatment under different scenarios. J Hepatol 2014;61:530-7.
9. Cramp ME, Rosenberg WM, Ryder S, Blach S, Parkes J. Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality. BMC Gastroenterol 2014;14:137.